Does risk prediction using NT-proBNP and hscTnI improve prediction of HF or MACE in the community compared to other biomarkers?
NT-proBNP and hscTnI are superior to other biomarkers for predicting HF and MACE in the community, supporting their use in designing biomarker-guided preventative trials.
The predictive characteristics of NT-proBNP and hscTnI for HF or MACE in the community are superior to other biomarkers. Biomarker-guided preventative interventions with reasonable efficacy would compare favourably to established preventative interventions. This data provides a framework for biomarker selection which may inform design of biomarker-guided preventative intervention trials.
AbouEzzeddine et al. (Tue,) studied this question.